ArticleFrontiers in medicine2026
Gelsolin amyloidosis presenting with nephrotic syndrome: a case report and molecular insights.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Amyloidosis of Finnish type (FAF) is a rare autosomal dominant hereditary amyloidosis associated with genetic variants of gelsolin. This condition is characterized by ophthalmologic abnormalities, progressive cranial neuropathy, and cutis laxa, while renal impairment is rare. We report a gelsolin amyloidosis in a 58-year-old man with nephrotic syndrome and slowly progressive kidney dysfunction, associated with a gelsolin gene mutation (c.480C > A, p.Asn160Lys). Initial renal biopsy showed segmental IgA deposition, moderate mesangial expansion with weak PAS positivity, and parallel bundles of 10 nm fibrils, but only trace Congo red staining. A second biopsy 2 years later revealed IgA-dominant deposition, nodular sclerosis, similar fibrils, glomerular basement membrane lamination, and weakly positive Congo red. The diagnosis of gelsolin amyloidosis was confirmed by mass spectrometry and immunohistochemistry. Clinically, the patient had no neuropathy or family renal disease but presented with gastrointestinal symptoms, and endoscopy confirmed vascular amyloid deposition. Molecular structure analysis suggested that the mutation may loosen the protein structure while preserving its calcium-binding ability. Combining with the literature, we discuss the clinicopathological features and predicted protein functions of mutated gelsolin, aiming to elucidate its pathogenic mechanisms and deepen the understanding of hereditary amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.